The superior body of the company is the Annual General Meeting, where the shareholders influence in the company is exercised. Shareholders who are registered in the share register held by VPC as of the record day and are registered pursuant to the Articles of Association have the right to participate at the Annual General Meeting, in person or by a representative. At the Annual General Meeting all shareholders have the same initiative, participation and voting rights.
At the Annual General Meeting Members of the Board are elected and when applicable also auditors, the manner in which the nomination committee shall be elected and if the Board of Directors and the CEO shall be discharged from liability for the fiscal year. Decisions are also made concerning establishment of financial reports, allocation of earnings, fees for the Board of Directors and the auditors, guidelines for remuneration of the CEO and other Managers and other essential matters that requires a decision by the Meeting. Normally decisions require a simple majority but the Swedish Companies Act dictates other criteria in certain matters.
Shareholders have the right to have an issue discussed at the Annual General Meeting. A notice of the Annual General Meeting will be published six to four weeks before the Meeting. In order for the company to include the issue in the notice, a request of issue discussion must reach the company 7 weeks before the Meeting. A request for an issue discussion at the Meeting shall be made to the Board of Directors and sent to the address given below:
Oasmia Pharmaceutical AB
Att. The Board of Directors
SE 752 28 Uppsala